Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Sep
18
2023
Report to Congress Identifies Significant Implications of Marijuana Rescheduling Wilson Elser Moskowitz Edelman & Dicker LLP
Sep
18
2023
Federal Trade Commission Warns Against Improper Orange Book Listings Foley & Lardner LLP
Sep
15
2023
McDermottPlus Check-Up: September 15, 2023 McDermott Will & Emery
Sep
15
2023
California Senate Passes AB 418 Keller and Heckman LLP
Sep
14
2023
California Fast Food Workers Look Forward to Pay Increases Vedder Price
Sep
14
2023
Research Finds Calories Often Absent from Food Delivery Platforms Keller and Heckman LLP
Sep
14
2023
Stark Integrity Podcast: FCA, CARES Act, and Call Arrangements Episodes [Podcast] Nelson Mullins
Sep
14
2023
NNCO Will Host Symposium on “Enabling the Nanotechnology Revolution” on October 10, 2023 Bergeson & Campbell, P.C.
Sep
14
2023
Key Takeaways | Hospital and Health System Digital Health Spotlight: It’s all About the Patient! McDermott Will & Emery
Sep
14
2023
Back to FAST Recovery: Business and Labor Reach Agreement Jackson Lewis P.C.
Sep
13
2023
FDA Sponsors Workshops on the Use of Meta-Analyses in Nutrition Research and Policy Keller and Heckman LLP
Sep
13
2023
Sua Sponte State Law Certification in Opioid MDL Appeal Squire Patton Boggs (US) LLP
Sep
12
2023
HHS Recommends Re-Classification of Marijuana as a Schedule III Controlled Substance – A Bellwether for the Future of Cannabis-ness Epstein Becker & Green, P.C.
Sep
12
2023
It’s Time to Move On: Litigation Regarding Alabama Medical Cannabis Commission Needs to Come to a Head Bradley Arant Boult Cummings LLP
Sep
12
2023
Another Heavy Metal Lawsuit Dismissed Keller and Heckman LLP
Sep
11
2023
DTC Promotional Labeling and Advertisements: Quantitative Efficacy Wins Over FDA in Final Guidance on Presenting Risk Information Foley & Lardner LLP
Sep
11
2023
Old North State Report – Sept. 11, 2023 Nelson Mullins
Sep
11
2023
FDA Issues Draft Guidance on Best Practices for Selecting Predicate Devices for 510(k) Notifications ArentFox Schiff LLP
Sep
11
2023
California Steps Up Liquor License Enforcement McDermott Will & Emery
Sep
8
2023
DOE and NSF Select Three Projects to Accelerate Biomanufacturing Innovation and Advance the U.S. Bioeconomy Bergeson & Campbell, P.C.
Sep
8
2023
Food & Chemicals Unpacked: The Notorious NAD: Challenge Accepted? Keller and Heckman LLP
Sep
8
2023
California Senate Removes Titanium Dioxide from AB 418 List of Prohibited Substances Keller and Heckman LLP
Sep
8
2023
FDA Issues Final Guidance on Informed Consent in Clinical Investigations McDermott Will & Emery
Sep
7
2023
France Reintroduces Bid to Ban Meat Names for Plant-Based Food Keller and Heckman LLP
Sep
7
2023
Context is Key: FDA Sends a Strong Message About Efficacy Claims Sheppard, Mullin, Richter & Hampton LLP
Sep
7
2023
EPA Posts Resources on Rule to Accelerate Use of PIPs Bergeson & Campbell, P.C.
Sep
6
2023
The Great Divide: The Feds’ Differing Approach to Psychedelics and Cannabis Bradley Arant Boult Cummings LLP
Sep
6
2023
Decentralized Clinical Trials: Sponsor Responsibilities Foley & Lardner LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins